Speaker Profile
PMWC PIONEER AWARD
Led the development and commercialization of Illuccix, helping doctors locate prostate cancer and identify patients eligible for targeted radioligand therapy.
Ph.D., CEO, Telix Pharma
Biography
Christian Behrenbruch, Ph.D., is Co-Founder, Managing Director, and Group Chief Executive Officer of Telix Pharmaceuticals, a global biopharmaceutical company developing diagnostic and therapeutic radiopharmaceuticals. He has more than 20 years of experience in healthcare, biotechnology, molecular imaging, and technology commercialization. Under his leadership, Telix has built an integrated radiopharmaceutical platform spanning prostate cancer imaging, targeted radiation therapy, manufacturing, and global commercialization. Dr. Behrenbruch has previously served as Chief Executive Officer of Mirada Solutions, President of CTI Molecular Imaging, and Chief Executive Officer of Fibron Technologies and ImaginAb, and he has held board and entrepreneurial roles across multiple life-science companies. He earned a D.Phil. in biomedical engineering from the University of Oxford, an MBA through TRIUM, and a law degree from the University of Melbourne, and is a Fellow of Engineers Australia. His work focuses on translating molecular targeting and radionuclide technology into scalable precision-oncology products and therapeutic platforms.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Razelle Kurzrock, Emory
PMWC Award Ceremony
• Antoni Ribas, UCLA Health (Luminary)
Featured Speakers
• Antoni Ribas, UCLA Health
• Gerold Meinhardt, Daiichi Sankyo
• Katy Rezvani, MD Anderson
• Javad Shahidi, BeOne
• Alicia Zhou, Cancer Research Institute
• Oren Gilad, Aprea Therapeutics
• Adam Palmer, UNC
• Trever Bivona, UCSF
• Laura Volta, Penn Medicine
• Vivek Subbiah, Stanford
• Mark Stewart, Friends of Cancer Research
Precision Immunotherapy After PD-1
Cells, bispecifics, ADCs, and new combination logic after checkpoint failure.
Biomarkers That Matter
Selecting patients for immunotherapy and targeted therapy with decision-grade biomarkers.
Resistance Biology & Adaptive Combination Strategies
How tumors adapt, and how to sequence therapy around that biology.
Which Immune Cells Can Be Programmed In Vivo?
The next wave of immune-cell engineering and where it may matter first.
Rare Cancers, Basket Trials & N-of-1 Playbooks
Moving from histology-agnostic evidence to individualized precision oncology.
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
